<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01266707</url>
  </required_header>
  <id_info>
    <org_study_id>560</org_study_id>
    <nct_id>NCT01266707</nct_id>
  </id_info>
  <brief_title>Antiangiogenic Peptide Vaccine Therapy in Treating Patient With Hepatocellular Carcinoma</brief_title>
  <official_title>Phase 1 Study of HLA-A*2402 Restricted Antiangiogenic Peptide Vaccine Therapy Using Epitope Peptide Derived Feom VEGFR1 and VEGFR2 in Treating Patients With Unresectable, Recurrent, or Metastatic Hepatocellular Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fukushima Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Human Genome Center, Institute of Medical Science, University of Tokyo</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Fukushima Medical University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess toxicities of angiogenic peptide vaccine therapy in
      treating HLA-A*2402 restricted patients with advanced hepatocellular carcinoma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      It has been required to develop new treatment modalities for patients with advanced
      heptatocellular carcinoma. Immunotherapy is one of the encouraging modalities for patients.
      We have to assess its toxicities, clinical response and immune responsiveness.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>March 2007</start_date>
  <completion_date type="Anticipated">March 2013</completion_date>
  <primary_completion_date type="Anticipated">March 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Toxicities as assessed by NCI-CACAE ver3</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Differences of peptide specific CTL response in vitro among sequence of peptide vaccine administration</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CD8 population</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in level of regulatory T cells</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response rate</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Feasibility</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">9</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <arm_group>
    <arm_group_label>Vaccine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>VEGRF1, VEGFR2</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>antiangiogenic paptide vaccine</intervention_name>
    <description>for drugs include administration time frame</description>
    <arm_group_label>Vaccine</arm_group_label>
    <other_name>VEGFR1 and VEGFR2 specific epitope vaccine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Unresectable or treatment-resistant patients with Hepatocellular carcinoma

          -  Measurable disease by CT scan

          -  ECOG performance status 0-2

          -  Life expectancy &gt; 3 months

          -  Laboratory values as follows: 2,000/mm3 &lt; WBC &lt;15,000/mm3, Platelet counts &gt;
             75,000/mm3, Total Bilirubin &lt; 1.5 mg/dl, Asparate transaminase &lt; 150IU/L, Alanine
             transaminase &lt; 150 IU/L, Creatinine &lt; 3.0mg/dl

          -  HLA-A*2402

          -  Able and willing to give valid written informed consent

        Exclusion Criteria:

          -  Pregnancy (women of childbearing potential: Refusal or inability to use effective
             means of contraception)

          -  Brest-feeder

          -  Active or uncontrolled infection

          -  Steroids or immunosuppressing agent dependent status

          -  Active or uncontrolled other malignancy

          -  Serious or uncured wound

          -  Decision of unsuitableness by principal investigator or physician-in charge
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mitsukazu Gotoh, PhD &amp; MD</last_name>
    <role>Study Chair</role>
    <affiliation>Fukushima Medical University, Department of Regeneration Surgery</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Akira Kenjo, MD</last_name>
    <phone>+81-24-547-1111</phone>
    <phone_ext>2332</phone_ext>
    <email>a-kenjo@fmu.ac.jp</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Takashi Kimura, MD, PhD</last_name>
    <phone>+81-24-547-1111</phone>
    <phone_ext>2332</phone_ext>
    <email>tkimura@fmu.ac.jp</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Fukushima Medical University Hospital</name>
      <address>
        <city>Fukushima</city>
        <zip>960-1295</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Akira Kenjo, MD</last_name>
      <phone>+81-24-547-1111</phone>
      <phone_ext>2332</phone_ext>
      <email>a-kenjo@fmu.ac.jp</email>
    </contact>
    <contact_backup>
      <last_name>Takashi Kimura, PhD &amp; MD</last_name>
      <phone>+81-24-547-1111</phone>
      <phone_ext>2332</phone_ext>
      <email>a-kenjo@fmu.ac.jp</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <reference>
    <citation>Niethammer AG, Xiang R, Becker JC, Wodrich H, Pertl U, Karsten G, Eliceiri BP, Reisfeld RA. A DNA vaccine against VEGF receptor 2 prevents effective angiogenesis and inhibits tumor growth. Nat Med. 2002 Dec;8(12):1369-75. Epub 2002 Nov 4.</citation>
    <PMID>12415261</PMID>
  </reference>
  <reference>
    <citation>Ishizaki H, Tsunoda T, Wada S, Yamauchi M, Shibuya M, Tahara H. Inhibition of tumor growth with antiangiogenic cancer vaccine using epitope peptides derived from human vascular endothelial growth factor receptor 1. Clin Cancer Res. 2006 Oct 1;12(19):5841-9.</citation>
    <PMID>17020992</PMID>
  </reference>
  <reference>
    <citation>Wada S, Tsunoda T, Baba T, Primus FJ, Kuwano H, Shibuya M, Tahara H. Rationale for antiangiogenic cancer therapy with vaccination using epitope peptides derived from human vascular endothelial growth factor receptor 2. Cancer Res. 2005 Jun 1;65(11):4939-46.</citation>
    <PMID>15930316</PMID>
  </reference>
  <verification_date>December 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 23, 2010</study_first_submitted>
  <study_first_submitted_qc>December 23, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 24, 2010</study_first_posted>
  <last_update_submitted>December 23, 2010</last_update_submitted>
  <last_update_submitted_qc>December 23, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 24, 2010</last_update_posted>
  <responsible_party>
    <name_title>Fukushima Medical University</name_title>
    <organization>Fukushima Medical University</organization>
  </responsible_party>
  <keyword>Hepatocellular carcinoma</keyword>
  <keyword>peptide vaccine</keyword>
  <keyword>VEGFR</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
    <mesh_term>Angiogenesis Inhibitors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

